pyruvic acid has been researched along with Acute Confusional Senile Dementia in 19 studies
Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed)
pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neurodegenerative disorders have been considered as a growing health concern for decades." | 2.61 | Mitochondrial metabolism: a common link between neuroinflammation and neurodegeneration. ( Agrawal, N; Garabadu, D; Sharma, A; Sharma, S, 2019) |
| " In this study, we evaluated protective effects of long-term administration of pyruvate in 3xTg-AD mice, a preclinical AD model that develops amyloid-β- and tau-dependent pathology." | 1.42 | Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without reducing amyloid and tau pathology. ( Bomba, M; Canzoniero, LM; Ciavardelli, D; Corona, C; Curcio, M; Granzotto, A; Isopi, E; Lattanzio, R; Navarra, R; Piantelli, M; Sensi, SL, 2015) |
| "The canine counterpart of senile dementia of the Alzheimer type (ccSDAT) is considered a promising model for examining behavioral, cellular and molecular processes involved in early phases of human brain aging and Alzheimer disease (AD)." | 1.33 | Severe cognitive impairment correlates with higher cerebrospinal fluid levels of lactate and pyruvate in a canine model of senile dementia. ( Andrade, C; Carrasco, JL; Mahy, N; Mas, E; Mascort, J; Pugliese, M, 2005) |
| "L-kynurenine (L-KYN) serves as a substrate for the synthesis of neurotoxic 3-OH-kynurenine (3-OH-KYN) and neuroprotective kynurenic acid (KYNA)." | 1.30 | Kynurenine metabolism in Alzheimer's disease. ( Baran, H; Deecke, L; Jellinger, K, 1999) |
| "The group with presenile dementia showed no uptake of amino acids, but a significant release of phenylalanine; in addition, CMR of alanine and threonine was significantly lower than in the healthy subjects." | 1.26 | Cerebral blood flow and metabolic rate of oxygen, glucose, lactate, pyruvate, ketone bodies and amino acids. ( Lindblad, BS; Lying-Tunell, U; Malmlund, HO; Persson, B, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 10 (52.63) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, D | 1 |
| Vincent, A | 1 |
| González-Gutiérrez, A | 1 |
| Aleyakpo, B | 1 |
| Anoar, S | 1 |
| Giblin, A | 1 |
| Atilano, ML | 1 |
| Adams, M | 1 |
| Shen, D | 1 |
| Thoeng, A | 1 |
| Tsintzas, E | 1 |
| Maeland, M | 1 |
| Isaacs, AM | 1 |
| Sierralta, J | 1 |
| Niccoli, T | 1 |
| Garabadu, D | 1 |
| Agrawal, N | 1 |
| Sharma, A | 1 |
| Sharma, S | 1 |
| Rossi, A | 1 |
| Rigotto, G | 1 |
| Valente, G | 1 |
| Giorgio, V | 1 |
| Basso, E | 1 |
| Filadi, R | 1 |
| Pizzo, P | 1 |
| Jin, N | 1 |
| Ziyatdinova, S | 2 |
| Gureviciene, I | 1 |
| Tanila, H | 2 |
| Popova, I | 1 |
| Malkov, A | 2 |
| Ivanov, AI | 1 |
| Samokhina, E | 1 |
| Buldakova, S | 1 |
| Gubkina, O | 1 |
| Osypov, A | 1 |
| Muhammadiev, RS | 1 |
| Zilberter, T | 1 |
| Molchanov, M | 1 |
| Paskevich, S | 1 |
| Zilberter, M | 2 |
| Zilberter, Y | 2 |
| Nilsen, LH | 1 |
| Witter, MP | 1 |
| Sonnewald, U | 1 |
| Kim, E | 1 |
| Jung, YS | 1 |
| Kim, H | 1 |
| Kim, JS | 1 |
| Park, M | 1 |
| Jeong, J | 1 |
| Lee, SK | 1 |
| Yoon, HG | 1 |
| Hwang, GS | 1 |
| Namkoong, K | 1 |
| Isopi, E | 1 |
| Granzotto, A | 1 |
| Corona, C | 1 |
| Bomba, M | 1 |
| Ciavardelli, D | 1 |
| Curcio, M | 1 |
| Canzoniero, LM | 1 |
| Navarra, R | 1 |
| Lattanzio, R | 1 |
| Piantelli, M | 1 |
| Sensi, SL | 1 |
| Thomas, SC | 1 |
| Alhasawi, A | 1 |
| Appanna, VP | 1 |
| Auger, C | 1 |
| Appanna, VD | 1 |
| Wang, X | 1 |
| Hu, X | 1 |
| Yang, Y | 1 |
| Takata, T | 1 |
| Sakurai, T | 1 |
| Bielarczyk, H | 1 |
| Jankowska-Kulawy, A | 1 |
| Höfling, C | 1 |
| Ronowska, A | 1 |
| Gul-Hinc, S | 1 |
| Roßner, S | 1 |
| Schliebs, R | 1 |
| Pawelczyk, T | 1 |
| Szutowicz, A | 1 |
| Hong, S | 1 |
| Quintero-Monzon, O | 1 |
| Ostaszewski, BL | 1 |
| Podlisny, DR | 1 |
| Cavanaugh, WT | 1 |
| Yang, T | 1 |
| Holtzman, DM | 1 |
| Cirrito, JR | 1 |
| Selkoe, DJ | 1 |
| Ivanov, A | 1 |
| Mukhtarov, M | 1 |
| Alpár, A | 1 |
| Tortoriello, G | 1 |
| Botting, CH | 1 |
| Fülöp, L | 1 |
| Osypov, AA | 1 |
| Pitkänen, A | 1 |
| Harkany, T | 1 |
| Pugliese, M | 1 |
| Carrasco, JL | 1 |
| Andrade, C | 1 |
| Mas, E | 1 |
| Mascort, J | 1 |
| Mahy, N | 1 |
| Lying-Tunell, U | 1 |
| Lindblad, BS | 1 |
| Malmlund, HO | 1 |
| Persson, B | 1 |
| Parnetti, L | 2 |
| Gaiti, A | 1 |
| Brunetti, M | 1 |
| Avellini, L | 1 |
| Polidori, C | 1 |
| Cecchetti, R | 1 |
| Palumbo, B | 1 |
| Senin, U | 1 |
| Baran, H | 1 |
| Jellinger, K | 1 |
| Deecke, L | 1 |
| Reboldi, GP | 1 |
| Gallai, V | 1 |
| Arias, C | 1 |
| Montiel, T | 1 |
| Quiroz-Báez, R | 1 |
| Massieu, L | 1 |
2 reviews available for pyruvic acid and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Mitochondrial metabolism: a common link between neuroinflammation and neurodegeneration.
Topics: Alzheimer Disease; Animals; Citric Acid Cycle; Humans; Mitochondria; Neurodegenerative Diseases; Neu | 2019 |
Brain metabolism and Alzheimer's disease: the prospect of a metabolite-based therapy.
Topics: Acetoacetates; Adenosine Triphosphate; Aluminum; Alzheimer Disease; Astrocytes; Brain; Carnitine; Hu | 2015 |
17 other studies available for pyruvic acid and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
A monocarboxylate transporter rescues frontotemporal dementia and Alzheimer's disease models.
Topics: Alzheimer Disease; Animals; Drosophila; Frontotemporal Dementia; Glucose; Humans; Neuroglia; Pyruvic | 2023 |
Defective Mitochondrial Pyruvate Flux Affects Cell Bioenergetics in Alzheimer's Disease-Related Models.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Energy Metabolism; Humans; Mitochondria; Pyruvic | 2020 |
Response of spike-wave discharges in aged APP/PS1 Alzheimer model mice to antiepileptic, metabolic and cholinergic drugs.
Topics: 3-Hydroxybutyric Acid; Action Potentials; Alzheimer Disease; Animals; Anticonvulsants; Atropine; Dis | 2020 |
Metabolic correction by pyruvate halts acquired epilepsy in multiple rodent models.
Topics: Alzheimer Disease; Animals; Anticonvulsants; Brain; Brain Waves; Drug Evaluation, Preclinical; Epile | 2017 |
Neuronal and astrocytic metabolism in a transgenic rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Astrocytes; Brain; Citric Acid Cycle; Disease Models, Animal; Female; ga | 2014 |
Metabolomic signatures in peripheral blood associated with Alzheimer's disease amyloid-β-induced neuroinflammation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Biomarkers; Disease Models, Animal; Encephalitis; | 2014 |
Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without reducing amyloid and tau pathology.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Calcium; Cells, Cultured; Cerebral Cortex; | 2015 |
Systemic pyruvate administration markedly reduces neuronal death and cognitive impairment in a rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Death; Cognition Disorders; Disease Models, | 2015 |
AβPP-Transgenic 2576 Mice Mimic Cell Type-Specific Aspects of Acetyl-CoA-Linked Metabolic Deficits in Alzheimer's Disease.
Topics: Acetyl Coenzyme A; Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Pre | 2015 |
Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation.
Topics: Age Factors; Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analys | 2011 |
Dietary energy substrates reverse early neuronal hyperactivity in a mouse model of Alzheimer's disease.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Ani | 2013 |
Severe cognitive impairment correlates with higher cerebrospinal fluid levels of lactate and pyruvate in a canine model of senile dementia.
Topics: Aging; Alzheimer Disease; Animals; Behavior, Animal; Biomarkers; Brain Chemistry; Cerebrospinal Flui | 2005 |
Cerebral blood flow and metabolic rate of oxygen, glucose, lactate, pyruvate, ketone bodies and amino acids.
Topics: Aged; Alzheimer Disease; Amino Acids; Brain; Cerebrospinal Fluid Shunts; Cerebrovascular Circulation | 1981 |
Increased CSF pyruvate levels as a marker of impaired energy metabolism in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Biomarkers; Case-Control Studies; Energy Metabolism; Female; Humans; Lactat | 1995 |
Kynurenine metabolism in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Caudate Nucleus; Female; Humans; Kinetics; Kynure | 1999 |
Cerebrospinal fluid pyruvate levels in Alzheimer's disease and vascular dementia.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Dementia, Vascular; Humans; Pyruvic Acid | 2000 |
beta-Amyloid neurotoxicity is exacerbated during glycolysis inhibition and mitochondrial impairment in the rat hippocampus in vivo and in isolated nerve terminals: implications for Alzheimer's disease.
Topics: Adenosine Triphosphate; Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; D | 2002 |